Nexpoint Asset Management’s Coherus Oncology CHRS Stock Holding History

Nexpoint Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-37,000	Closed	-$268K	–	150
2022 Q2	$268K	Hold	37,000	–	–	0.02%	113
2022 Q1	$478K	Hold	37,000	–	–	0.06%	99
2021 Q4	$591K	Hold	37,000	–	–	0.08%	120
2021 Q3	$595K	Hold	37,000	–	–	0.1%	101
2021 Q2	$512K	Hold	37,000	–	–	0.11%	93
2021 Q1	$541K	Sell	37,000 -3,000	-8%	-$50.9K	0.14%	86
2020 Q4	$695K	Sell	40,000 -30,000	-43%	-$534K	0.23%	88
2020 Q3	$1.28M	Sell	70,000 -42,385	-38%	-$789K	0.29%	67
2020 Q2	$2.01M	Sell	112,385 -5,000	-4%	-$84.6K	0.45%	44
2020 Q1	$1.9M	Sell	117,385 -7,440	-6%	-$137K	0.36%	42
2019 Q4	$2.25M	Hold	124,825	–	–	0.17%	78
2019 Q3	$2.53M	Buy	+124,825	New	+$2.49M	0.16%	96

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nexpoint Asset Management's CHRS Position: Q3 2022 in Review

Nexpoint Asset Management sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 37,000 shares — an estimated $268K sold.

Nexpoint Asset Management first reported a position in CHRS in Q3 2019 and held it in 12 quarters. The position peaked at $2.53M in Q3 2019. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

Nexpoint Asset Management reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
Nexpoint Asset Management sold 37,000 Coherus Oncology shares in Q3 2022, an estimated $268K.
Nexpoint Asset Management first reported a position in Coherus Oncology in Q3 2019 and held it in 12 quarters.
Nexpoint Asset Management's Coherus Oncology position peaked at $2.53M in Q3 2019.
174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on Nexpoint Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.